ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater China
FURVENT Phase 3 topline data for firmonertinib still expected in second half of 2026 as ArriVent posts $373.1 million in cash and investments.
SEC filing
Latest
2 stories
Sign in